Learning objectives
By the end you can:
- Explain the generics business model from first principles: why a legal invention (Hatch-Waxman's bioequivalence shortcut) created the industry, how the file → approve → launch → erode cycle works, and why a generics company is a treadmill whose speed is set by US price erosion (mid-to-high single digits in a normal year; always verify the current rate) against a launch cadence it must fund with 6–9% of sales in R&D.
- Compute the economics of a Para IV / first-to-file 180-day exclusivity window: revenue, gross profit, and the post-exclusivity cliff. Explain why an exclusivity windfall is valued as a one-time cash flow, never capitalized at a P/E multiple.
- Read the USFDA compliance ladder (Form 483 → OAI classification → Warning Letter → Import Alert → consent decree), stating precisely what each step blocks (new approvals vs existing shipments), the typical market reaction, and the 2–4 year remediation arc.
- Explain why complexity is margin in generics: why injectables, respiratory, ophthalmics, peptides and biosimilars erode at 2–5% instead of 8–12%, and why India's domestic branded generics business earns 25%+ EBITDA margins that the US commodity business cannot.
- Run the hospital KPI panel: ARPOB, occupancy (healthy 70–75%), ALOS, EBITDA per bed split mature vs new, payer/case mix. Value a hospital chain on EV/EBITDA cross-checked by EV/bed, and model the greenfield J-curve versus the brownfield shortcut.
- Run the diagnostics panel: volume growth vs revenue per patient, B2C vs B2B mix, hub-and-spoke network economics. Apply the post-COVID normalization lesson: never put a growth multiple on windfall earnings.
- Spot the sector's red flags: a Warning Letter or Import Alert on a plant that carries the US pipeline, US revenue eroding with no complex pipeline behind it, debt-funded bed additions crushing blended margins, realization falling faster than volume can grow. Connect each to a real casualty (Ranbaxy, Teva, and the 2022 diagnostics de-rating).
- Deliver the Phase 5 pharma case: a full three-lens workup (one Indian generics company against a US peer, plus one Indian hospital or diagnostics company) graded against the rubric below.
Prerequisites & connections
Builds on. From Phase 4: the moat lenses matter here in an unusual way, because most of a generics company's US portfolio has no moat at all (that is what erosion is), so the analysis becomes a hunt for the pockets that do (complexity barriers, plant approvals as a cornered resource, brand equity in Indian prescriptions). M4.03's five-forces work returns with the sharpest buyer-power case you will ever see: three US purchasing consortia buying from over a hundred sellers. From Phase 3: NPV/IRR logic (M3.02) prices the exclusivity windfall; the ROIC > WACC master test (M3.07) is the hospital section's spine, because a hospital in year 2 of its J-curve earns 2% on capital while the same building at maturity earns 25%. From Phase 2: segment analysis (M2.04), because a pharma P&L means nothing until you split US / India / rest-of-world and, inside hospitals, mature beds from new beds. From Phase 1: capitalization vs expensing of R&D (M1.06) and contingent liabilities (M1.08), since pharma balance sheets carry litigation the P&L has not met yet.
Feeds into. M5.08 (autos & industrials) reuses the capacity-utilization and capex-cycle grammar you learn on hospital beds. Phase 7's macro work touches this sector twice: US drug-pricing politics and the rupee (a 1% INR depreciation is roughly a 30–40 bp gross-margin gift to an exporter with rupee costs). Phase 8's rapid teardown uses the material here as its "regulated manufacturer" and "capacity services" branches. Competency C6 continues: within two minutes of opening any healthcare annual report you should be able to say which of the three playbooks applies, then refuse to value a hospital on P/E or a generics company on EV/bed.
4.1 Why this sector is three businesses, not one
"Pharma & healthcare" is a filing-cabinet label, not an economic category. The cabinet holds at least three fundamentally different machines: